Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prevail Therapeutics

- PMLiVE

Eli Lilly shares positive late-stage results for Retevmo in thyroid cancer

Medullary thyroid cancer only accounts for up to 2% of thyroid cancers in the US

regeneron headquarters

Regeneron to acquire Decibel Therapeutics in deal worth up to $213m

The transaction expands the company’s gene therapy and hearing loss pipeline

- PMLiVE

Eli Lilly announces positive results for Retevmo in phase 3 lung cancer study

Non-small cell lung cancer accounts for up to 85% of all lung cancer cases in the US

- PMLiVE

NICE publishes draft guidance not recommending CSL’s haemophilia B gene therapy

The company has been seeking approval for use of the therapy in adults with severe or moderately severe haemophilia B without a history of factor IX inhibitors

- PMLiVE

Eli Lilly and Boehringer’s Jardiance granted EC approval to treat chronic kidney disease

Approximately 47 million people in the EU are affected by the long-term kidney condition

- PMLiVE

Eli Lilly’s Alzheimer’s drug confirmed to significantly slow disease progression

The full phase 3 results presented at AAIC reinforce the cognitive benefits of donanemab

- PMLiVE

Eli Lilly to acquire Versanis in deal worth over $1.9bn

The deal marks a significant boost to the company’s cardiometabolic disease pipeline

- PMLiVE

Eli Lilly to acquire Sigilon in deal worth over $300m

The companies have been working together since 2018 on cell therapies for type 1 diabetes

- PMLiVE

FDA approves BioMarin’s Roctavian as first gene therapy for severe haemophilia A

Approximately 2,500 patients are expected to be eligible to receive the one-time therapy

- PMLiVE

FDA grants accelerated approval to Sarepta’s Duchenne muscular dystrophy gene therapy

The disease occurs in up to one in every 5,000 newborn males worldwide

- PMLiVE

Eli Lilly to acquire Dice Therapeutics for approximately $2.4bn

The deal marks a significant expansion to Lilly's immunology pipeline

- PMLiVE

Decision date for Sarepta’s Duchenne muscular dystrophy gene therapy delayed by FDA

The disease occurs in up to one in every 5,000 newborn males worldwide

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links